» Articles » PMID: 17010049

Oxidative Stress and Inflammation in Iron-overloaded Patients with Beta-thalassaemia or Sickle Cell Disease

Overview
Journal Br J Haematol
Specialty Hematology
Date 2006 Oct 3
PMID 17010049
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Blood transfusion therapy is life-saving for patients with beta-thalassaemia and sickle cell disease (SCD), but often results in severe iron overload. This pilot study examined whether the biomarkers of tissue injury or inflammation differ in these two diseases. Plasma malondialdehyde (MDA) was significantly increased 1.8-fold in thalassaemia relative to control patients. In contrast, MDA in SCD was not significantly different from controls. In multivariate analysis, the strongest predictors of elevated MDA were liver iron concentration (P < 0.001) and specific diagnosis (P = 0.019). A significant 2-fold elevation of non-transferrin bound iron (NTBI) was observed in thalassaemia relative to SCD. NTBI was not a significant predictor of high MDA in multivariate analysis. SCD patients showed a significant 2.2-fold elevation of the inflammatory marker interleukin (IL)-6 relative to controls, and a 3.6- and 1.7-fold increase in IL-5 and IL-10 relative to thalassaemia. Although alpha-tocopherol was significantly decreased by at least 32% in both thalassaemia and SCD, indicating ongoing oxidant stress and antioxidant consumption, gamma-tocopherol, a nitric oxide-selective antioxidant, was increased 36% in SCD relative to thalassaemia. These results demonstrate that thalassaemia patients have increased MDA and circulating NTBI relative to SCD patients and lower levels of some cytokines and gamma-tocopherol. This supports the hypothesis that the biology of SCD may show increased inflammation and increased levels of protective antioxidants compared with thalassaemia.

Citing Articles

Cardiac injury caused by iron overload in thalassemia.

Fu C, Yang X Front Pediatr. 2025; 13:1514722.

PMID: 39931654 PMC: 11808023. DOI: 10.3389/fped.2025.1514722.


Iron in ventricular remodeling and aneurysms post-myocardial infarction.

Wang Z, Ding X, Pan J, Wang X, Lin J, Wang X Open Med (Wars). 2024; 19(1):20241109.

PMID: 39669378 PMC: 11635762. DOI: 10.1515/med-2024-1109.


Association of serum ferritin trends with liver enzyme patterns in β-thalassemia major: A longitudinal correlational study.

Rabadiya S, Yogesh M, Nagda J, Gandhi R, Makwana N J Family Med Prim Care. 2024; 13(7):2698-2702.

PMID: 39070990 PMC: 11272003. DOI: 10.4103/jfmpc.jfmpc_1897_23.


Deferoxamine Intradermal Delivery Patch for Treatment of a Beta-Thalassemia Wound.

Perrault D, Chattopadhyay A, Sivaraj D, Wan D, Chen K, Gurtner G Ann Surg Open. 2024; 5(1):e372.

PMID: 38883943 PMC: 11175915. DOI: 10.1097/AS9.0000000000000372.


Focus on Paediatric Restrictive Cardiomyopathy: Frequently Asked Questions.

Zampieri M, Di Filippo C, Zocchi C, Fico V, Golinelli C, Spaziani G Diagnostics (Basel). 2023; 13(24).

PMID: 38132249 PMC: 10742619. DOI: 10.3390/diagnostics13243666.


References
1.
Finch C, Lee M, Leonard J . Continuous RBC transfusions in a patient with sickle cell disease. Arch Intern Med. 1982; 142(2):279-82. View

2.
Jain S, SHOHET S . A novel phospholipid in irreversibly sickled cells: evidence for in vivo peroxidative membrane damage in sickle cell disease. Blood. 1984; 63(2):362-7. View

3.
Hebbel R, MILLER W . Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood. 1984; 64(3):733-41. View

4.
Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C . Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27-30. DOI: 10.1016/s0140-6736(89)90264-x. View

5.
Wickramasinghe S, Thein S, Srichairatanakool S, Porter J . Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type I. Br J Haematol. 1999; 107(3):522-5. DOI: 10.1046/j.1365-2141.1999.01745.x. View